Gamma Biosciences, A Life Sciences Platform Established By KKR, Announces Sale Of Mirus Bio To Merck KGaA, Darmstadt, Germany, For $600M
Author: Benzinga Newsdesk | May 23, 2024 08:09am
Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, today announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
Posted In: KKR